Joonghun Pharmaceutical Has Launched Artgaon to Compete With Top European Fillers
30.3.2021 12:00:00 EEST | Business Wire | Press release
Joonghun Pharmaceutical has officially launched their premium cross-linked hyaluronic acid dermal filler, Artgaon.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005456/en/
Joonghun Pharmaceutical has officially launched their premium cross-linked hyaluronic acid dermal filler, Artgaon (Photo: Business Wire)
Artgaon, with its certification of the CE mark, is specifically aimed to target the European aesthetic market as its slogan states “The Finest, for European Professionals”. Joonghun Pharmaceutical is a pharmaceutical company in South Korea that specializes in Hyaluronic Acid Injections used in orthopedic treatments for 15 years. With their in-depth knowledge of HA characteristics, they were able to develop a dermal filler designed to compete against the top European brands in the aesthetics industry.
According to Dr. YeoHye Yoon, the Quality Director from Joonghun, the main vision for Artgaon during its product development was to provide a new aesthetic experience like no other for both the patient and practitioner. To deliver this experience, Artgaon was focused on two things: high quality and unique cross-linking technology.
Artgaon is manufactured under strict pharmaceutical guidelines despite dermal fillers being classified as medical devices. “This commitment enables us to have higher standards of safety for every component of the filler. For example, Artgaon is manufactured in cleanrooms that control particles as small as 10-micrometers. Naturally, this makes Artgaon extremely clean, which we believe would add to the confidence of doctors using our product.”
Artgaon’s unique cross-linking technology allows doctors to enjoy an injection force of a mere 7-8 newtons that is smooth and consistent. Despite this, Artgaon boasts high elastic (G prime) and cohesive properties when inside the skin. Joonghun claims that their formula for Artgaon shows natural results not only by looks but by experiences felt by patients as well. “Artgaon really allows the doctor to mold the beauty they want for their patients due to the low injection force coupled with high molding capabilities.”
The gel characteristics of Artgaon is to be expressed in their soon to be updated package designs. “Artgaon’s new package designs are based on the architectural structure of the industrial era, which remain firm and capture beauty even to this day. We wanted this architectural beauty from the industrial era to represent Artgaon’s gel structure; to be firm and attain its beauty even over time.”
The quality and performance of Artgaon has already surprised doctors who have tested Artgaon. It is only a matter of time until Artgaon disrupts the beauty market of Europe and the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005456/en/
Contact information
Tulay Genc | info@b2press.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“Moutai Night” Makes Seoul Debut, Celebrating China–South Korea Cultural Exchange3.11.2026 15:17:00 EET | Press release
On October 25, the 2026 “Moutai Night” was held in Seoul, South Korea, under the theme “Born by the Chishui River, Fragrance Along the Han River.” Over a hundred guests from China and South Korea gathered around the Han River, sharing the distinctive appeal of Chinese baijiu, and fostering cultural exchange between the two countries through fine liquor and culture. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103333206/en/ “Moutai Night” Makes Seoul Debut, Celebrating China–South Korea Cultural Exchange The event featured an exhibition on Moutai’s brewing techniques and brand history. Hands-on experiences with Miao batik and silverwork showcased Guizhou culture, while creative cocktails brought Chinese spirits into dialogue with Korean tastes. A city-themed video, dance performances and a violin performance rounded out the program, as guests exchanged views on liquor culture in a warm atmosphere. As a flagship cultural
TVS Motor Company Strengthens Its European Presence With Four Production-Ready Models at EICMA 20263.11.2026 15:14:00 EET | Press release
TVS Motor Company, the world's third-largest two-wheeler manufacturer, today unveiled four production-ready models at EICMA 2026 in Milan, reinforcing its commitment to Europe as a strategic market. The showcase highlights products developed for European customers, supported by dedicated engineering capabilities, an expanding retail network, and the strengths of TVS Motor's global manufacturing, technology and product development ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103474635/en/ TVS Motor Company unveils 4 new products at EICMA 2026. Left to right: Vimal Sumbly, Manu Saxena, Giovanni Furnari and Peyman Kargar The four models, the TVS Orbiter, TVS M1-S, TVS X and TVS RTR 125, reflect TVS Motor's approach to serving Europe's evolving mobility needs across electric commuting, premium urban transportation and lightweight sports motorcycling. Together, they demonstrate the company's ability to combine mar
Teamily AI Reports 32× Quarterly User Growth, Positive Gross Margins, and Strong Global Adoption of Human–Agent Collaboration3.11.2026 15:00:00 EET | Press release
Teamily AI, a human–agent collaboration platform that enables people and AI agents to work together in a unified, context-aware workspace, today announced significant growth and commercial milestones following a quarter of rapid global expansion. The company grew from 10,000 to 320,000 sign-ups in a single quarter, a 32× increase that works out to a compound monthly growth rate of 217.5%, just three months after its public launch in July 2026. With positive gross margins on paying users, and growing adoption among professional teams and businesses, Teamily AI establishes a foundation for scalable product-led growth (PLG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103047955/en/ 32× Global Growth in One Quarter Teamily AI grew from 10,000 to 320,000 registered users across more than 100 countries in one quarter, representing 32× growth and a 217.5% compound monthly growth rate. According to publicly available Similarwe
Fourthline and Veridas Complete Merger to Create a European Leader in Bank-Grade Digital Identity3.11.2026 14:40:00 EET | Press release
Fourthline and Veridas today announce the completion of their merger, first announced on 16 July 2026. The transaction closed on 3 November 2026 following the satisfaction of all closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103282546/en/ The funding will be used to accelerate product innovation, pursue strategic M&A, refinance debt, and support a shareholding reorganization that includes partial liquidity for Veridas shareholders. Both businesses will be EBITDA-positive at close. The combination is expected to deliver €20m in annual run-rate synergies. With limited customer overlap and complementary markets, most of that growth will come from offering each company's proprietary technology underpinning the full scope of IDV products to the other's customers. Leadership and governance Fourthline CEO, Paul Stoddart, will lead the combined entity as Chief Executive Officer. Finch Capital Managing Partner
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the third quarter 2026 financial results and business highlights. "Compass is leading one of the most important advances in mental health care in decades. Millions of people living with TRD are waiting for new treatments that can deliver meaningful and lasting benefit, and we believe COMP360 has the potential to change the paradigm," said Kabir Nath, Chief Executive Officer of Compass Pathways. “With the imminent completion of our NDA submission and the potential for a quick approval, we are executing with urgency and discipline to launch this much needed treatment in the first half of 2027. At the same time, we continue to advance our PTSD program, extending the potential impact of COMP360 to additional patient populations with significant unmet need. With a robust clinical package, a clear path forward, and a launch-ready orga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom